Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamara Bavendam

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
American Journal of Obstetrics and Gynecology|June 18, 2002
Hormonal manipulation in women with chronic, cyclic irritable bladder symptoms and pelvic painGretchen M Lentz, Tamara Bavendam, Morton A Stenchever, et al.
The Journal of Urology|April 21, 2009
Bother related to bladder control and health care seeking behavior in adults in the United StatesJoshua S Benner, Russell Becker, Kristina Fanning, et al.
Neurourology and Urodynamics|March 11, 2009
The psychometric validation of the OAB family impact measure (OAB-FIM)Karin S Coyne, Louis S Matza, Jessica Brewster-Jordan, et al.
Neurourology and Urodynamics|August 22, 2012
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trialsCatherine E DuBeau, Jon D Morrow, Stephen R Kraus, et al.
The American Journal of Managed Care|April 10, 2009
Challenges for managing overactive bladder and guidance for patient supportVernon F Schabert, Tamara Bavendam, Erica L Goldberg, et al.
The Journal of Sexual Medicine|May 15, 2007
Overactive bladder and women's sexual health: what is the impact?Karin S Coyne, Mary Kay Margolis, Zhanna Jumadilova, et al.
BJU International|May 31, 2008
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom ScoreSteven A Kaplan, Claus G Roehrborn, Michael Chancellor, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|June 5, 2009
Efficacy and tolerability of fesoterodine in women with overactive bladderPeter K Sand, Jon D Morrow, Tamara Bavendam, et al.
Urology|October 24, 2021
A Scoping Review of the Economic Burden of Non-Cancerous Genitourinary ConditionsMichelle M Kim, Joshua Harvey, Andrew Gusev, et al.
Current Medical Research and Opinion|March 2, 2011
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptomsHarriette Scarpero, Peter K Sand, Con J Kelleher, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
American Journal of Obstetrics and Gynecology|June 18, 2002
Hormonal manipulation in women with chronic, cyclic irritable bladder symptoms and pelvic painGretchen M Lentz, Tamara Bavendam, Morton A Stenchever, et al.
The Journal of Urology|April 21, 2009
Bother related to bladder control and health care seeking behavior in adults in the United StatesJoshua S Benner, Russell Becker, Kristina Fanning, et al.
Neurourology and Urodynamics|March 11, 2009
The psychometric validation of the OAB family impact measure (OAB-FIM)Karin S Coyne, Louis S Matza, Jessica Brewster-Jordan, et al.
Neurourology and Urodynamics|August 22, 2012
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trialsCatherine E DuBeau, Jon D Morrow, Stephen R Kraus, et al.
The American Journal of Managed Care|April 10, 2009
Challenges for managing overactive bladder and guidance for patient supportVernon F Schabert, Tamara Bavendam, Erica L Goldberg, et al.
The Journal of Sexual Medicine|May 15, 2007
Overactive bladder and women's sexual health: what is the impact?Karin S Coyne, Mary Kay Margolis, Zhanna Jumadilova, et al.
BJU International|May 31, 2008
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom ScoreSteven A Kaplan, Claus G Roehrborn, Michael Chancellor, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|June 5, 2009
Efficacy and tolerability of fesoterodine in women with overactive bladderPeter K Sand, Jon D Morrow, Tamara Bavendam, et al.
Urology|October 24, 2021
A Scoping Review of the Economic Burden of Non-Cancerous Genitourinary ConditionsMichelle M Kim, Joshua Harvey, Andrew Gusev, et al.
Current Medical Research and Opinion|March 2, 2011
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptomsHarriette Scarpero, Peter K Sand, Con J Kelleher, et al.
Pageof 6